会社概要
- 正式社名: Beijing Kawin Technology Share-Holding Co.,Ltd
- 登録国: China
- 住所: No.6 Rongjing East Street, BDA, Beijing, China, Beijing
- 従業員数: 500 - 999
説明:
Focused on viral and immune diseases, Kawin offers mature products built on its specialty in interferon strain management to EP standards, and provides product licensing opportunities including a portfolio of glycyrrhizin products used in dermatology and hepatology, with transfer of interferon and G-CSF (both conventional and pegylated) open to discussion.
事業活動
バイオ医薬品
原薬メーカー
バイオ医薬品サービス
原薬メーカー
ATC分類(解剖治療化学分類)
原薬メーカー
販売市場
- East Asia: China, Democratic People's Republic of Korea, Mongolia, Republic of Korea, Japan, Taiwan
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Western Asia: United Arab Emirates, Armenia, Azerbaijan, Bahrain
当社の製品・サービス
Sell · Active Pharmaceutical Ingredients (APIs)
Sell · ATC (Anatomical Therapeutic Chemical) Classification
認証
証明
CPHI & PMEC China 2026
06/2026 – 06/2026
CPHI & PMEC China 2026
評価
(0)
(0)
(0)
(0)
(0)
コメント
フィルター:
並べ替え:
コメントはありません。
評価とコメントを残す